% | $
Quotes you view appear here for quick access.

VIVUS Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • balhara balhara Feb 27, 2012 10:30 PM Flag

    Question to the board?

    this question was specifically discussed at adcom, and panel favor post-approval study.

    fda panel has to weight risk of any side effect, with unmet need. in this case, there is not sufficient evidence of risk, to let patients with unmet need wait for this drug. hence, post-approval study.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Point taken and appreciate your opinion. I understand this is an unmet need, but what if the side effects outweigh the benefits? Wouldn't the FDA request pre-approval study just to make sure the product is safe? On the other side, I can also see this to be post-approval since the FDA had time ( and didn't though) to request pre-approval study and they haven't at this time, so why would they come next month or days before the FDA decision and say, oh we'd need a pre-approval study? not that they've done this before, but given all the time they had and never made it a requisite

2.53-0.05(-1.94%)May 22 4:00 PMEDT